Ethypharm’s Post

📢 Ethypharm expands its Mesalazine Portfolio in China Ethypharm is pleased to announce the acquisition of a suppository form of Mesalazine by its Chinese affiliate. Mesalazine is a medication used to treat Inflammatory Bowel Diseases (IBD) such as ulcerative colitis and Crohn’s disease. This strategic acquisition will enable to better meet the needs of patients and healthcare professionals in China by offering a broader portfolio of Mesalazine formulations. To learn more please visit our newsroom 👉 https://lnkd.in/eqau33cd #Ethypharm #Healthcare #Pharma #GrowthStrategy #China #patients #essentialmedicines #acquisition